Relmada Therapeutics, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
21.38
|
|
Average Rating
|
3.67
|
|
# Strong Buys
|
2
|
|
# Buys
|
0
|
|
# Holds
|
4
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-1.45
|
-1.31
|
0.14
|
9.66%
|
|
2022-06-30
|
-1.27
|
-1.33
|
-0.06
|
-4.72%
|
|
2022-03-31
|
-1.27
|
-1.40
|
-0.13
|
-10.24%
|
|
2021-12-31
|
-1.83
|
-1.80
|
0.03
|
1.64%
|
|
2021-09-30
|
-1.60
|
-2.44
|
-0.84
|
-52.50%
|
|
2021-06-30
|
-1.47
|
-1.56
|
-0.09
|
-6.12%
|
|
2021-03-31
|
-1.39
|
-1.34
|
0.05
|
3.60%
|
|
2020-12-31
|
-1.16
|
-1.31
|
-0.15
|
-12.93%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-1.31
|
|
2022-06-30
|
-6.97
|
|
2021-06-30
|
-5.26
|
|
2020-06-30
|
-2.22
|
|
2019-06-30
|
-1.13
|
|
2018-06-30
|
-1.30
|
|
2017-06-30
|
-2.07
|
|
2016-06-30
|
-0.30
|
|
2015-06-30
|
-10.37
|